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Abstract
Background: A large number patients struggle with migraine which is classified as a chronic disorder. The relative
efficacy, safety and tolerability of prophylactic medications for migraine play a key role in managing this disease.
Methods: We conducted an extensive literature search for popular prophylactic medications that are used for
migraine patients. Pairwise meta-analysis and network meta-analysis (NMA) were carried out sequentially for
determining the relative efficacy, safety and tolerability of prophylactic medications. Summary effect for migraine
headache days, headache frequency, at least 50% reduction in headache attacks, all-adverse events, nausea,
somnolence, dizziness, withdrawal and withdrawal due to adverse events were produced by synthesizing both
direct and indirect evidence.
Results: Patients with three interventions exhibited significantly less average migraine headache days compared
with those treated by placebo (topiramate, propranolol, divalproex). Moreover, topiramate and valproate exhibited a
significantly increased likelihood of at least 50% reduction in migraine headache attacks compared to placebo.
Patients with topiramate and propranolol also exhibited significantly reduced headache frequency compared to
those with placebo. On the other hand, patients with divalproex exhibited significantly higher risk of nausea
compared to those with placebo, topiramate, propranolol, gabapentin and amitriptyline. Finally, divalproex was
associated with an increased risk of withdrawal compared to placebo and propranolol.
Conclusions: Topiramate, propranolol and divalproex may be more efficacious than other prophylactic
medications. Besides, the safety and tolerability of divalproex should be further verified by future studies.
Keywords: Migraine, Efficacy, Safety, Tolerability, Network meta-analysis
Background
Migraine is a chronic neurological disorder with high
prevalence. Females appeared to have a higher morbidity of
migraine than males in developed countries [1]. Although a
relatively small number of migraine cases were reported in
Asia, the morbidity of migraine attack in this region can
reach up to 9.3% [2]. Throbbing headache is usually accom-
panied with migraine, resulting in both poor productivity
and unstable emotional state [3, 4]. Migraine patients are
often managed by medications which are convenient and
efficient. However, side effects such as nausea and dizziness
resulted from these medications have been observed in
patients who exhibited poor level of tolerance [5].
Two types of medications have been introduced to
patients: abortive and preventative medications [6]. The
above two types of medications differ considerably in
their mechanisms: abortive treatments attenuate symp-
toms arise from acute migraine attacks whereas pre-
ventative medications specifically aim at reducing attack
severity and frequency. Although several prophylactic
medications have been developed for migraine patients,
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no consensus has been reached with respect to their
relative efficacy, safety and tolerability [7]. Furthermore,
some medications appear to provide inadequate relief
since they are not effective to all migraine patients [8].
As a result, some meta-analysis has been designed to
compare the relative efficacy between different medica-
tions and some conclusions have been obtained in the
current literature. For instance, patients treated by
sodium valproate were associated with a lower risk of
headache compared to the control group [9]. Further-
more, triptans and non-triptans appear to provide
patients with different levels of relief [10].
Nevertheless, the current literature does not contain
adequate studies that are able to identify the most pref-
erable prophylactic medication for migraine patients and
there is an increasing demand for discriminating the
available medications with respect to their efficacy, safety
and tolerability. For this purpose, we compared several
preventative medications for migraine patients by using
the approach of network meta-analysis (NMA) and we
expect this approach can provide more insights for the
selection of prophylactic medications.
Methods
Search strategy
The medical literature for relevant studies in PubMed
and EMBASE were systematically searched using elec-
tronic search strategies, and 1315 records were identified
through searching the following key words, for example
“migraine”, “topiramate”, “propranolol”, “gabapentin”,
“amitriptyline”, “divalproex” and “valproate”. Two add-
itional references were obtained from reviewers. As flow
chart Fig. 1 illustrates, 556 duplicated records were
identified and removed. Another 486 irrelevant studies
were excluded from the remaining 761 records and a
final 32 studies were subject to full-text review (Table 1).
Exclusion criteria
Articles were excluded in our study according to the
following criteria: (1) the diagnose of migraine was
not firmly confirmed in the study; (2) contain treat-
ments that cannot form a closed network; (3) have
no comparisons between different treatments; (4)
contain outcomes without proper information; (5)
does not have any relevant clinical outcomes or
treatments; (6) studies without blinding procedures
or studies with sample size less than 30; (7) non-
randomized clinical trials such as reviews. A study
was not considered to be eligible if any of the above
criteria was fulfilled.
Outcome measures, data extraction and comparator
network formation
We selected several clinical outcomes in order to
measure the relative efficacy, safety and tolerability of
prophylactic migraine medications: monthly migraine
headache days, headache frequency, the percentages
of patients with at least 50% reductions in migraine
attacks (efficacy), the number of patients with all ad-
verse events such as nausea, somnolence or dizziness
(safety) and the number of patients who withdrew
from studies (tolerability). The following data were
extracted from eligible studies and shown in Table 1,
including country of study, sample size, histology and
clinical outcomes. The corresponding data were
extracted into a database after two independent inves-
tigators reviewed the manuscripts of all the studies. A
Jaded scale table was produced for the purpose of
study quality assessment (Additional file 1: Table S1).
After data extraction was performed for each study, a
network plot with respect to each clinical outcome
was produced for demonstrating direct and indirect
comparisons (Figs. 2, 3 and 4).
1,315 records identified 
through database searching 
2 additional references from 
reviewers found 
1,317 records identified and 556 
duplicates removed 
275 studies included 





















Full-text articles excluded: 
Treatment cannot form a network 
Treatment not compared with others 
Outcomes without proper information 
486 studies excluded 
Fig. 1 Flow chart of literature identification, search and inclusion
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Statistical analysis
We implemented a two-step approach in our system
review and evidence synthesis. Firstly, a conventional
pairwise meta-analysis was carried out in order to pool
all direct evidence in the current literature. For con-
tinuous outcomes such as monthly migraine headache
days and headache frequency, raw mean differences
(MD) between two groups were synthesized and a sum-
mary effect was produced based on raw mean differ-
ences, sample size and sample standard deviation. We
selected raw mean differences for evidence synthesis
since all eligible studies reported the above continuous
outcomes in the same scale. On the other hand, the
statistic of odds ratio (OR) was pooled from each eli-
gible study and a summary OR was produced for each
binary outcome. The pairwise meta-analysis was imple-
mented based on the random-effects model because we
did not have full knowledge of study participants or im-
plementation for each eligible study [11].
The second step in our study involves conducting a
NMA by synthesize both direct and indirect evidence.
Similar to the pairwise meta-analysis, summary mean















Fig. 2 Network plots of eligible comparisons of migraine intervention (monthly migraine headache days; headache frequency; ≥50% reduction in
migraine headache attacks). A: Placebo; B: Topiramate; C: Propranolol; D: Gabapentin; E: Amitriptyline; F: Divalproex; G: Valproate. Direct




























Fig. 3 Network plots of eligible comparisons for adverse events (all adverse events; nausea; somnolence; dizziness) A: Placebo; B: Topiramate; C:
Propranolol; D: Gabapentin; E: Amitriptyline; F: Divalproex; G: Valproate. Direct comparisons were connected by solid lines whereas indirect
comparisons were connected by dashed lines
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differences and summary ORs were produced using
the Bayesian framework and the Markov Chain
Monte Carlo (MCMC) sampling technique. The
corresponding ranking of each intervention was ob-
tained by using the surface under the cumulative
ranking curve (SUCRA). If an intervention exhibited a
higher SUCRA value compared to other interventions,
then it is potentially more preferable than others with
respect to an endpoint. After that, the assumption of
consistency between direct and indirect evidence was
assessed by using the node-splitting method whereas
publication bias was visually inspected by using
funnel plots [12, 13].
Results
Description of included studies
The prescribed searching strategy and exclusion cri-
teria enabled us to identify and include 32 studies with
a total number of 6052 subjects (Table 1) [14–45]. All
included studies were carried out by using single or
double blinding procedures. These studies were car-
ried out between 1986 and 2015 with a maximum
following-up duration of 1 year. The majority of the
included studies belonged to typical randomized
controlled trials (RCTs), however, we identified and in-
cluded five crossover RCTs in which participants were
randomized to receive a sequence of interventions.











Fig. 4 Network plots of eligible comparisons for discontinued cases (all-cause withdrawal; withdrawal due to AEs). A: Placebo; B: Topiramate; C:
Propranolol; D: Gabapentin; E: Amitriptyline; F: Divalproex; G: Valproate. Direct comparisons were connected by solid lines whereas indirect
comparisons were connected by dashed lines
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Monthly Migraine Headache Days Headache Frequency  
 ≥50% Reduction in Migraine Headache Attacks 
Comparison with Placebo MD  (95% CrI) 
Topiramate 1.20 (0.70, 1.80)
Propranolol 0.95 (0.08, 1.80)
Amitriptyline 1.10 (-0.89, 3.10)
Divalproex 1.30 (0.28, 2.40)
0 49.0-
Topiramate 1.20 (0.35,  2.00)
Propranolol 1.40 (0.29, 2.50)
Gabapentin 1.20 (-0.90, 3.30)
Divalproex 0.60 (-1.20, 2.40)
Valpromate 0.84 (-0.79, 2.50)
0 42-





  12.0 (1.40, 1.1e+02)
1 0022.0
































































OR (95% CrI) Comparison with Placebo
Fig. 6 Forest plots of summary effects (NMA) with respect to all adverse events, nausea, dizziness and somnolence




























Comparison with Placebo OR (95% CrI) 
Fig. 7 Forest plots of summary effects (NMA) with respect to all-cause withdrawal and withdrawal due to AEs
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Pairwise comparison using conventional meta-analysis
A total of ten direct comparisons with respect to each
endpoint were produced by using pairwise meta-analysis
(Table 2). Patients with topiramate exhibited significantly
less average headache days, less headache frequency, a
higher likelihood of at least 50% reduction compared to
those with placebo (migraine headache days: −0.28, 95%
CI = −0.53 to −0.03; headache frequency: −0.31, 95% CI
= −0.45 to −0.17; ≥ 50% reduction: OR = 2.33, 95% CI =
1.58–3.42). However, patients with topiramate appeared
to have significantly higher risk of all-adverse events and
withdrawal due to adverse events compared to those
with placebo (all-adverse events: OR = 1.35, 95% CI =
1.06–1.73, withdrawal due to adverse events: OR = 2.08,
95% CI = 1.56–2.78). Patients with propranolol exhibited
a significantly less average headache days but higher risk
of all-adverse events, somnolence and withdrawal due to
adverse events compared to those with placebo (mi-
graine headache days: −0.29, 95% CI = −0.49 to −0.09;
all-adverse events: OR = 2.02, 95% CI = 1.05–4.08,
Monthly Migraine Headache Days Headache Frequency  
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Fig. 9 Probability ranking plot of all adverse events, nausea, dizziness and somnolence
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somnolence: OR = 4.33, 95% CI = 1.21 to 15.53, with-
drawal due to adverse events: OR = 1.87, 95% CI =
1.09 to 3.09). Although there is no significant differ-
ences in the average migraine days, headache fre-
quency or the likelihood of at least 50% reduction in
headache attacks between patients with gabapentin
and those with placebo, gabapentin appeared to be
associated with an increased risk of somnolence and
dizziness (somnolence: OR = 2.23, 95% CI = 1.11 to
4.46; dizziness: OR = 3.13, 95% CI = 1.73 to 5.56). Pa-
tients treated with amitriptyline or divalproex exhib-
ited a reduced headache days or headache frequency
as well as a better performance in at least 50%
reduction in headache attacks compared to those with
placebo (amitriptyline: headache frequency: −0.36,
95% CI = −0.62 to −0.10; ≥ 50% reduction: OR = 1.81,
95% CI = 1.03–3.20; divalproex: migraine headache
days: −0.40, 95% CI = −0.61 to −0.18; ≥ 50% reduc-
tion: OR = 4.27, 95% CI = 1.30–13.99), however, this
was offset by an increased risk of all-adverse events
or nausea (amitriptyline: all-adverse events: OR = 2.20,
95% CI = 1.04–4.66; divalproex: nausea: OR = 2.23,
95% CI = 1.21–4.10). Besides that, we were not able to
identify any significant results between direct compar-
isons produced by conventional meta-analysis. Be-
sides, propranolol was safer comparing to topiramate
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Fig. 11 Clustering of migraine interventions. Interventions with the same level of efficacy, safety or tolerability are shown in the same color.
Interventions located in the top right corner were more preferable than those in the lower left corner
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(all-adverse events: OR = 0.57, 95% CI = 0.36–0.90;
withdrawal: OR = 0.66, 95% CI = 0.44–0.99; withdrawal
due to adverse events: OR = 0.58, 95% CI = 0.37–0.91).
Including both direct and indirect evidence in the NMA
Results produced by NMA are displayed in Table 3
which determined the relative efficacy, safety and toler-
ability of prophylactic migraine interventions by using
both direct and indirect evidence. Patients with three in-
terventions exhibited significantly less average migraine
headache days compared with those treated by placebo
(topiramate: −1.20, 95% CrI = −1.83 to −0.70; propran-
olol: −0.98, 95% CrI = −1.86 to −0.07; divalproex: −1.28,
95% CrI = −2.44 to −0.27; Table 3, Fig. 5). Moreover,
patients with topiramate and valproate exhibited a sig-
nificantly increased likelihood of at least 50% reduction
in migraine headache attacks compared to those with
placebo (topiramate: OR = 4.28, 95% CrI = 1.35 to 14.70;
valproate: 11.38, 95% CrI = 1.31 to 111.11; Table 3,
Fig. 5). Patients with topiramate or propranolol also
Fig. 12 Node-splitting method for assessing consistency with
respect to headache frequency
Fig. 13 Node-splitting method for assessing consistency with respect to all adverse events, nausea and dizziness
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exhibited significantly reduced headache frequency
compared to those with placebo (topiramate: −1.17,
95% CrI = −1.98 to −0.35; propranolol: −1.37, 95%
CrI = −2.49 to −0.29; Table 3, Fig. 5).
Our NMA also provides results for the relative
safety of migraine interventions. Patients with Dival-
proex exhibited significantly higher risk of nausea
compared to those with placebo, topiramate, propran-
olol, gabapentin and amitriptyline (all ORs > 1).
Furthermore, patients with amitriptyline exhibited a
significantly elevated risk of all-adverse events
compared to those with propranolol or placebo (all
ORs > 1). However, patients with amitriptyline exhib-
ited a significantly reduced risk of all-adverse events
compared to those with divalproex (OR = 0.24, 95%
CrI = 0.07 to 0.85). Patients with topiramate also ex-
hibited significantly higher risk of all adverse events
compared to those with placebo (OR = 2.44, 95% CrI =
1.55 to 3.88; Table 3, Fig. 6). Our NMA also discov-
ered that patients with GABAPENTIN were associated
with a significantly increase in the risk of dizziness in
comparison to those received placebo (OR = 3.69, 95%
CrI = 1.17 to 9.63; Table 3, Fig. 6). The relative toler-
ability of various migraine interventions were assessed
by using the endpoints of all-cause withdrawal and
withdrawal due to adverse events. As suggested by
Table 3 and Fig. 7, patients with divalproex exhibited a
significantly increased risk of all-case withdrawal com-
pared to those with propranolol or placebo (propran-
olol: OR = 2.09, 95% CrI = 1.11 to 4.52; placebo: OR =
1.68, 95% CrI = 1.14 to 3.67). On the other hand,
patients treated with topiramate or divalproex were
associated with an increased risk of withdrawals due
to adverse events compared to those with placebo
(topiramate: OR = 2.33, 95% CrI = 1.55 to 3.45; dival-
proex: OR = 2.25, 95% CrI = 1.01 to 5.49).
Ranking of migraine interventions using SUCRA values
A ranking plot with respect to each endpoint was pro-
duced and a SUCRA table was created in order to
differentiate the above migraine interventions (Figs. 8,
9 and 10, Additional file 2: Table S2). Divalproex
appeared to have the largest SUCRA value with re-
spect to migraine headache days. Propranolol, topira-
mate and gabapentin exhibited the largest three
SUCRA values with respect to headache frequency.
Moreover, valproate, topiramate and divalproex were
more preferable than other interventions with respect
to the endpoint of at least 50% reduction in migraine
attacks. A similar ranking scheme was produced for
the above interventions with respect to their safety
and tolerability (Additional file 2: Table S2). We also
conducted a cluster analysis for grouping the above
prophylactic migraine interventions based on the
Fig. 14 Node-splitting method for assessing consistency with
respect to all-cause withdrawal and withdrawal due to AEs
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SUCRA values of two endpoints. Overall, propranolol
seemed to be the most desirable intervention when
several endpoints were simultaneously considered
(Fig. 11).
Assessing consistency between direct and indirect
evidence
Since we implemented a consistency model when
conducting the NMA, the node-splitting method was
used to assess the validity of this assumption
(Figs. 12, 13 and 14). Net heat plots were also
produced by software in order to visualize the
consistency pattern existed in each comparison
(Figs. 15, 16 and 17). As suggested by both the node
splitting method (P-value > 0.05) and net heat plots,
there is no significant inconsistency between direct
and indirect evidence for the majority of compari-
sons. Therefore, we concluded that the consistency
model is valid in our NMA.
Assessing publication bias using funnel plots
Potential publication bias contained in our NMA was
evaluated by using the funnel plots produced by software
(Additional file 3: Figures S1, Additional file 4: Figure S2
and Additional file 5: Figure S3). As suggested by the
funnel plots, there is no significant asymmetry pattern
and most studies were evenly distributed in the funnel
plot. Therefore, we concluded that there is no significant
publication bias in our study.
Discussion
Migraine is a chronic disabling disease accompanied
with recurrent headache. Patients with migraine often
suffer from throbbing headache and preventative
therapies have been introduced to reduce the risk of
migraine onset. Several medications have been ap-
plied to migraine patients as prophylaxis and most of
these medications are able to reduce the monthly
attack frequency by 50% [46]. We conducted an ex-
tensive literature review and NMA in order to deter-
mine the relative efficacy, safety and tolerability of six
popular prophylactic migraine interventions: topira-
mate, propranolol, gabapentin, amitriptyline, dival-
proex and valproate.
Results of our NMA indicated that three interventions
may be particularly efficacious for reducing the corre-
sponding symptoms of migraine: divalproex, propranolol
and valproate. In our study, divalproex ranked the high-
est with respect to the reduction of monthly headache
days whereas propranolol appeared to be the most pref-
erable intervention for reducing headache frequency.
Moreover, our study also suggested that valproate exhib-
ited superior performance with respect to at least 50%
reduction in headache attacks. Accordingly to the
American Academy of Neurology (AAN) and the Ameri-
can Society of Headache (AHS), divalproex is classified
as level-A medication and it is offered to patients for mi-
graine prophylaxis [47]. Another study conducted by
Kaniecki et al. revealed that both divalproex and
propranolol significantly reduced headache frequency
and the number of headache days compared to placebo,
Fig. 15 Net heat plot of study designs with respect to monthly migraine headache days and headache frequency. The area of the gray
squares displays the contribution of the direct estimate in design d (shown in the column) to the network estimate in design d
(shown in the row). The colors are associated with the change in inconsistency between direct and indirect evidence (shown in the row)
after detaching the effect (shown in the column). Blue colors indicate an increase and warm colors indicate a decrease (the stronger the
intensity of the color, the stronger the change)
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however, there was no significant difference in the
efficacy between the two interventions [48]. The
above conclusions were verified by our NMA which
did not suggest any significant difference in the effi-
cacy between divalproex and propranolol. As sug-
gested by AAN and AHS, valproate is also classified
as level-A medication that should be offered to mi-
graine patients [49]. The efficacy of valproate in redu-
cing migraine attacks has been verified by several
studies, for instance, Sørensen et al. was the first one
who suggested that valproate exhibited a noteworthy
effect on patients with severe migraine with respect
to migraine prophylaxis [50]. Although our study
suggested that patients with valproate were more
likely to experience at least 50% reduction in mi-
graine attacks than those with placebo, the wide
confidence interval resulted from potential inconsist-
ency or inadequate evidence should be addressed by
conducting large-scale studies in order to verify the
above conclusions.
Apart from efficacy, the safety of migraine medica-
tion is another predominating factor that must be
considered by physicians when selecting an appropri-
ate intervention. As suggested by previous studies,
migraine patients treated by antiepileptic drugs may
experience several side-effects, including nausea,
dizziness and paresthesia [51]. One significant result
produced by our NMA is that patients with dival-
proex exhibited a significantly increased risk of
nausea compared to those with placebo or other
interventions. This result was confirmed by our
SUCRA ranking tables in which the SUCRA value of
Fig. 16 Net heat plot of study designs with respect to all adverse events, nausea, dizziness and somnolence
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divalproex appeared to be the lowest with respect to
the endpoint of nausea. Apart from that, our pairwise
meta-analysis discovered that patients with divalproex
were associated with a significantly increased risk of
nausea compared to those with placebo. Furthermore,
our NMA revealed that patients with divalproex may
have poor medication compliance since they appeared
to have an increased risk of withdrawal. We urged fu-
ture researchers to design and conducted prospective
studies in order to confirm the safety of divalproex.
Despite that some new findings have been suggested
by our study, it is essential to discuss several key issues
that may have impact on our conclusions. Firstly, we
include both RCTs and crossover studies in our NMA;
this may significantly increase the heterogeneity resulted
from the design and implantation of different studies.
For instance, crossover studies involves randomly assign-
ing a sequence of interventions to different groups over
the study period, therefore, the randomization technique
used in crossover studies was completely different from
that in RCTs. However, the inclusion of crossover stud-
ies did not enable us to adjust for the corresponding se-
quences where a serious of treatments was assigned.
Furthermore, the inclusion of crossover studies pro-
duced some extra confounding factors that were not
presented in RCTs. For instance, a wash-out period
between interventions is often used in crossover studies
and the duration of the wash-out period may have sig-
nificant impact on medication compliance as well as on
the corresponding endpoints. Our NMA did not adjust
for the corresponding dose used for each intervention
either. The above uncontrolled factors may independ-
ently affect our conclusion or interacted with each other,
producing significant effect modification. Nevertheless,
the corresponding conclusions and limitations under-
lying our study provide researchers with key guidelines
for designing new trials or prospective studies for
migraine patients.
Conclusions
Our NMA suggested that topiramate, propranolol and
divalproex may be more efficacious than other prophy-
lactic medications. However, based on the above limita-
tions, our results need to be interpreted with caution.
Besides, safety and tolerability of divalproex should be
further verified by future studies.
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